Year: 2022
Type: dissertation
Abstract: I examined how pharmacologically induced changes of the microbiome by pro- or antibiotics influenced the expression of stem cell markers in the intestines of laboratory mice. C57BL/6 inbred mice were treated with probiotics (a mixture of Lactobacilli and Bifidobacteria), the non-absorbable antibiotic rifaximin or a broad-spectrum mixture of antibiotic drugs (ampicillin, neomycin sulfate, vancomycin, metronidazole; AMT) for two weeks. As a main result, AMT induced a significant downregulation of Lgr5, Rnf43 and Ascl2 in large bowel of mice. In a clinical pilot study I investigated the association of the altered intestinal microbiome with the expression levels of intestinal stem cell markers in a cohort of patients with expected compositional microbiome differences: healthy controls (n = 10), study subjects with inflammatory bowel disease (n = 9), or with metabolic syndrome (n = 7). I found a significant upregulation of Olfm4 in patients with ulcerative colitis. The microbial analysis showed a clear decrease of microbial variety with a shift towards more abundant Firmicutes (phylum) and changing profiles of bacterial families in the groups of patients with metabolic syndrome and UC compared to the fecal microbiomes of healthy individuals.
Authors: Eberl, Julia Verena, Gerhard, Markus 1968-, Technische Universität München
Institution: Technical University of Munich
Language: English
Topic: Gut microbiota and health
Subfield: Molecular Biology
Domain: Life Sciences
Keywords: gut microbiota, intestinal stem cells, stem cell markers, probiotics, lactobacilli, Bifidobacterium, antibiotic-induced dysbiosis, rifaximin, broad-spectrum antibiotics, Lgr5, RNF43, ASCL2, OLFM4, inflammatory bowel disease, ulcerative colitis, metabolic syndrome, Firmicutes, fecal microbiota, C57BL/6 mice
Open Access status: green
OpenAlex ID: W7037603791
